The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and
decompensated heart failure.
Author(s): Dandamudi S, Chen HH.
Affiliation(s): Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Publication date & source: 2012, Expert Rev Cardiovasc Ther. , 10(5):557-63
Nesiritide has been approved by the US FDA for the treatment of acute
decompensated heart failure since 2001. Subsequently, two meta-analyses
questioned its impact on mortality and association with worsening renal function.
Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in
Decompensated Heart Failure trial was designed to assess the safety and efficacy
of nesiritide in acute decompensated heart failure based on clinically relevant
outcomes. In this article, the important findings and lessons learned from this
landmark study are reviewed and potential evolving roles for nesiritide and
natriuretic peptides in the future of heart failure therapy are proposed.
|